Tradenames starting with "V"

Patents whose numbers are in italics have been extended under 35 USC 156. All expiration dates include applicable Sec. 156 and pediatric (PED) extensions.


Varizig (For Injection) (Intramuscular) Varicella Zoster Immune Globulin (Human)
Drug Classes: Immunological Agents:Immunoglobulins == Immunological Agents:Vaccines
NDA Applicant: Kamada Ltd.      BLA No.: 125430  Prod. No.: 002 Rx (125IU) BLA No.: 125430  Prod. No.: 001 Disc (125IU)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityDec 20, 2019Orphan Designation: Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella
Approved Labeled Indication: Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella

Vaxneuvance (Injection) (Intramuscular) Pneumococcal 15-valent Conjugate Vaccine
Drug Classes: Immunological Agents:Vaccines
NDA Applicant: Merck Sharp & Dohme Corp.      BLA No.: 125741  Prod. No.: 001 Rx (2.0UG)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Ref. Product ExclusivityJul 16, 2033 

Vimizim (Injection) (Intravenous) elosulfase alfa
Drug Classes: Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment == hydrolytic lysozomal glycosaminoglycan (GAG)-specific enzyme
NDA Applicant: BioMarin Pharmaceutical Inc.      BLA No.: 125460  Prod. No.: 001 Rx (5MG/5ML (1MG/ML))
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityFeb 14, 2021Orphan Designation: Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)
Approved Labeled Indication: Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)
Exclusivity Protected Indication: Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)

Vonvendi (For Injection) (Intravenous) von Willebrand factor (Recombinant)
Drug Classes: Blood Products and Modifiers:Blood Component Deficiency/ Replacement == human blood coagulation factor
NDA Applicant: Baxalta US Inc.      BLA No.: 125577  Prod. No.: 001 Rx (1300IU); 002 Rx (650IU)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityDec 8, 2022Orphan Designation: Treatment of von Willebrand disease
Approved Labeled Indication: Indicated for on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease (VWD)
Exclusivity Protected Indication: Indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease (VWD)
Exclusivity Type: Orphan Drug ExclusivityApr 13, 2025Orphan Designation: Treatment of von Willebrand disease
Approved Labeled Indication: Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding
Exclusivity Protected Indication: Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding

Voraxaze (For Injection) (Intravenous) glucarpidase
Drug Classes: carboxypeptidase
NDA Applicant: BTG International Inc.      BLA No.: 125327  Prod. No.: 001 Rx (1,000UNITS)
ExclusivityExpirationExclusivity Description
Exclusivity Type: Orphan Drug ExclusivityJan 17, 2019Orphan Designation: Treatment of patients at risk of methotrexate toxicity
Approved Labeled Indication: Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.



Last edited: 15 November 2022
© 2001-2022 Bruce A. Pokras, All rights reserved worldwide